Chemomab Therapeutics Ltd.
CMMBAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | Aug 27, 2025 |
| Oppenheimer | maintain | Outperform | May 16, 2025 |
| Maxim Group | maintain | Buy | Feb 20, 2025 |
| Oppenheimer | maintain | Outperform | Nov 15, 2024 |
| Oppenheimer | upgrade | Perform →Outperform | May 6, 2024 |
| Oppenheimer | maintain | Perform | Mar 8, 2024 |
| Oppenheimer | downgrade | Outperform →Perform | Jun 7, 2023 |
| Oppenheimer | maintain | Outperform | Apr 18, 2023 |
| Oppenheimer | maintain | Outperform | Mar 10, 2022 |
| Aegis Capital | maintain | Buy | Dec 7, 2021 |
| Cantor Fitzgerald | maintain | Overweight | May 26, 2021 |
| Oppenheimer | maintain | Outperform | May 7, 2021 |
Earnings History
Next report: Mar 10, 2027 · EPS est. $-0.01| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 19, 2026 | $-0.27 | $-0.15 | — | — |
| May 14, 2026 | $-0.22 | $-0.04 | — | — |
| Mar 19, 2026 | $-0.24 | $-0.20 | — | — |
| Nov 13, 2025 | $-0.02 | $-0.20 | — | — |
| Aug 14, 2025 | $-0.36 | $-0.20 | — | — |
| May 15, 2025 | $-0.56 | $-0.20 | — | — |
| Mar 3, 2025 | $-0.64 | $-0.20 | — | — |
| Nov 14, 2024 | $-0.80 | $-0.04 | — | — |
News
Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (Nasdaq: CMMB) (“Chemomab”) and Scipher Medicine Corporation (“Scipher”), a leader in immunology precision medicine, today announced that on October 30, 2026, the U.S. Securities and Exchange Commission (“SEC”) declared effective the Registration Statement on Form S-4 (as amended, the “Registration State…
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C.
Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end